Owners, management and financials
CVR: 19064301
Secondary names: AVENTIS A/S, RHONE-POULENC RORER A/S, HOECHST MARION ROUSSEL A/S
DKK 442,343,000
Revenue
Net result: DKK 5,043,000
Sanofi-Aventis Participations (100%)
CVR · view owners
Odd Arne Gabriel Johannessen
Board: Birgitte Fyhn (chair) and 2 members
CVR · view management
Active
Founded 15 January 1996
CVR · view overview
98 employees
CVR · 2018
Director registered: Odd Arne Gabriel Johannessen
CVR · 06/03/2025
View the full event history
Sanofi A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Odd Arne Gabriel Johannessen. The board consists of Birgitte Fyhn (chair), Hao Zheng and Odd Arne Gabriel Johannessen. The company is owned by Sanofi-Aventis Participations. The company has 98 employees (2018). In 2025, the company reported revenue of DKK 442,343,000 and a net result of DKK 5,043,000 compared with DKK 6,217,000 the year before. Equity in the 2025 report amounted to DKK 58,663,000.
Source: annual report 2025, Danish Business Authority
Sanofi A/S is experiencing a declining trend in revenue and profitability, with 2025 revenue at 442.3 million DKK and profit at 5 million DKK, down from 591.1 million DKK in 2021 and a peak profit of 21.9 million DKK. The company's equity has shown modest growth, reaching 58.7 million DKK in 2025, but overall profit margins have decreased significantly, raising concerns about operational efficiency. As a player in the wholesale trade of pharmaceuticals and healthcare products, Sanofi A/S faces challenges in maintaining its market position amidst fluctuating financial performance. The declining revenue and profit trajectory suggests a need for strategic adjustments to enhance profitability and stabilize its financial health.
AI-generated summary · Generated 01/07/2026
Selskabets formål er at drive handel og produktion af farmaceutiske produkter og alle aktiviteter, der relaterer sig til research, udvikling, produktion, udnyttelse og marketing af bio-farmaceutiske og farmaceutiske produkter, inklusive vacciner, serummer, immummodulatoer og produkter afledt fra bio-teknologi og højteknologi beregnet til humanmedicinske lægemidler.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 442.3 mio. | 5 mio. | 232.8 mio. | 58.7 mio. | 78000 | |
| 202401/01/2024 – 31/12/2024 | 452.6 mio. | 6.2 mio. | 192 mio. | 53.6 mio. | 81 | |
| 202301/01/2023 – 31/12/2023 | 527.6 mio. | 3.7 mio. | 166.2 mio. | 47.4 mio. | 83 | |
| 202201/01/2022 – 31/12/2022 | 530.9 mio. | 15.9 mio. | 179.9 mio. | 43.7 mio. | 85 | |
| 202101/01/2021 – 31/12/2021 | 591.1 mio. | 22 mio. | 223.2 mio. | 69.3 mio. | 86 | |
| 202001/01/2020 – 31/12/2020 | 563.5 mio. | 67.2 mio. | 225.8 mio. | 77.2 mio. | 100 | |
| 201901/01/2019 – 31/12/2019 | 485.7 mio. | 7.2 mio. | 164.7 mio. | 23.3 mio. | 99 | |
| 201801/01/2018 – 31/12/2018 | 433.9 mio. | -3.1 mio. | 176.8 mio. | 16.1 mio. | 97 | |
| 201701/01/2017 – 31/12/2017 | 421.2 mio. | 11.6 mio. | 160.4 mio. | 19.2 mio. | 95 | |
| 201601/01/2016 – 31/12/2016 | 435.5 mio. | 7.7 mio. | 191.3 mio. | 32.5 mio. | 87 | |
| 201501/01/2015 – 31/12/2015 | 393.2 mio. | 26.1 mio. | 192 mio. | 59.9 mio. | 74 | |
| 201401/01/2014 – 31/12/2014 | 304.3 mio. | 25 mio. | 160 mio. | 68.7 mio. | 69 | |
| 201301/01/2013 – 31/12/2013 | 255.3 mio. | -16.2 mio. | 162.3 mio. | 78.7 mio. | 52 |
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
23 public tenders won
Showing 10 of 23 contracts
See all won contracts on UdbudsScannerSources: TED (the EU tender database) and udbud.dk
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Sanofi A/S is 19064301.
Sanofi A/S is owned by Sanofi-Aventis Participations.
The management of Sanofi A/S consists of Odd Arne Gabriel Johannessen.
The board of Sanofi A/S consists of Birgitte Fyhn, Hao Zheng and Odd Arne Gabriel Johannessen, with Birgitte Fyhn as chair.
In 2025, Sanofi A/S reported revenue of DKK 442,343,000.
Sanofi A/S had 98 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Sanofi A/S has won the tender "Rammeaftale om køb af Beyfortus (nirsevimab)" issued by Amgros I/S worth 70,000,000 DKK.
Sanofi A/S has published its annual report for 2025. Revenue came to DKK 442,343,000, and the net result was DKK 5,043,000.
Sanofi A/S has won the tender "Amgros 2026 1.1219.a" issued by Amgros I/S worth 7,171,109 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.615.b" issued by Amgros I/S worth 48,195,968 DKK.
Sanofi A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.604.a" issued by Amgros I/S worth 501,367,776 DKK.
Sanofi A/S has won the tender "Amgros 2026 2.210.a" issued by Amgros I/S worth 102,909,186 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.702.b" issued by Amgros I/S worth 22,987,384 DKK.
Sanofi A/S has won the tender "Udbud af rammekontrakter vedr. rabiesvacciner og TBE-vacciner" issued by Statens Serum Institut worth 1 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.966.a" issued by Amgros I/S worth 840,000,000 DKK.
Sanofi A/S has published its annual report for 2024. Revenue came to DKK 452,617,000, and the net result was DKK 6,217,000.
Sanofi A/S has won the tender "Rammeaftale om køb af Xenpozyme (olipudase alfa)" issued by Amgros I/S worth 14,000,000 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.713.a" issued by Amgros I/S worth 861,000 DKK.
As of March 6, 2025, Odd Arne Gabriel Johannessen is registered as director of Sanofi A/S.
As of March 6, 2025, Daniel Andreas Sandgren has stepped down as director of Sanofi A/S.
As of March 4, 2025, Odd Arne Gabriel Johannessen has joined the board of directors of Sanofi A/S.
As of March 4, 2025, Hao Zheng has joined the board of directors of Sanofi A/S.
As of March 4, 2025, Peter Wester Oldenziel has left the board of directors of Sanofi A/S.
As of March 4, 2025, Daniel Andreas Sandgren has left the board of directors of Sanofi A/S.
Sanofi A/S has won the tender "Amgros 2025 1.855.a" issued by Amgros I/S worth 436,800,000 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.350.a" issued by Amgros I/S worth 20,097,600,000 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.1070.a" issued by Amgros I/S worth 583,800,000 DKK.
Sanofi A/S has won the tender "Udbud af rammeaftale om influenzavaccine" issued by Statens Serum Institut worth 1 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.958.b" issued by Amgros I/S worth 326,700,000 DKK.
As of November 25, 2024, Birgitte Fyhn has joined the board of directors of Sanofi A/S.
As of November 25, 2024, Kirstin Jagd has left the board of directors of Sanofi A/S.
Sanofi A/S has won the tender "Amgros 2025 1.356.a" issued by Amgros I/S worth 4,530,400,000 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.1205.a" issued by Amgros I/S worth 73,155,425 DKK.
As of September 2, 2024, Daniel Andreas Sandgren has joined the board of directors of Sanofi A/S.
As of September 2, 2024, Fiona Sylvie Simone de Bouvere has left the board of directors of Sanofi A/S.
As of September 2, 2024, Daniel Andreas Sandgren is registered as director of Sanofi A/S.
As of September 2, 2024, Fiona Sylvie Simone de Bouvere has stepped down as director of Sanofi A/S.
Sanofi A/S has won the tender "Amgros 2025 1.1172.a" issued by Amgros I/S worth 1,360,000 DKK.
Sanofi A/S has published its annual report for 2023. Revenue came to DKK 527,584,000, and the net result was DKK 3,697,000.
As of June 28, 2024, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of Sanofi A/S.
As of June 28, 2024, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Sanofi A/S.
Sanofi A/S has won the tender "Amgros 2024 1.342.b" issued by Amgros I/S worth 16,200,000 DKK.
Sanofi A/S has won the tender "Amgros 2024 1.1166.a" issued by Amgros I/S worth 501,900,000 DKK.
As of April 2, 2024, Fiona Sylvie Simone de Bouvere has joined the board of directors of Sanofi A/S.
As of April 2, 2024, Rasmus Villemoes has left the board of directors of Sanofi A/S.
As of April 2, 2024, Fiona Sylvie Simone de Bouvere is registered as director of Sanofi A/S.
As of April 2, 2024, Rasmus Villemoes has stepped down as adm. dir. of Sanofi A/S.
Sanofi A/S has won the tender "Udbud af rammekontrakt vedrørende pertussis vaccine (kighoste) 2024-2028" issued by Statens Serum Institut worth 1 DKK.
Sanofi A/S has published its annual report for 2022. Revenue came to DKK 530,879,000, and the net result was DKK 15,919,000.
Sanofi A/S has published its annual report for 2021. Revenue came to DKK 591,149,000, and the net result was DKK 21,982,000.
Sanofi A/S has published its annual report for 2020. Revenue came to DKK 563,450,000, and the net result was DKK 67,215,000.
Sanofi A/S has published its annual report for 2019. Revenue came to DKK 485,721,000, and the net result was DKK 7,223,000.
Sanofi A/S has published its annual report for 2018. Revenue came to DKK 433,862,252, and the net result was DKK -3,056,222.
As of February 14, 2019, Peter Wester Oldenziel has joined the board of directors of Sanofi A/S.
As of February 14, 2019, Charlotte Søby Vestergaard has left the board of directors of Sanofi A/S.
As of September 7, 2018, Rasmus Villemoes is registered as adm. dir. of Sanofi A/S.
As of September 7, 2018, Charlotte Søby Vestergaard has stepped down as adm. dir. of Sanofi A/S.
Sanofi A/S has published its annual report for 2017. Revenue came to DKK 421,220,000, and the net result was DKK 11,630,000.
Sanofi A/S has published its annual report for 2016. Revenue came to DKK 435,538,000, and the net result was DKK 7,689,000.
Sanofi A/S has published its annual report for 2015. Revenue came to DKK 393,188,000, and the net result was DKK 26,123,000.
As of April 13, 2016, Kirstin Jagd has joined the board of directors of Sanofi A/S.
As of April 13, 2016, Rasmus Villemoes has joined the board of directors of Sanofi A/S.
As of April 13, 2016, Charlotte Søby Vestergaard has joined the board of directors of Sanofi A/S.
As of April 13, 2016, Lasse Richter Petersen has left the board of directors of Sanofi A/S.
As of April 13, 2016, Minna Satu Marketta Kallio has left the board of directors of Sanofi A/S.
As of April 13, 2016, Charlotte Søby Vestergaard is registered as adm. dir. of Sanofi A/S.
As of April 13, 2016, Lasse Richter Petersen has stepped down as adm. dir. of Sanofi A/S.
As of April 12, 2016, Kirstin Jagd has left the board of directors of Sanofi A/S.
Sanofi A/S has published its annual report for 2014. Revenue came to DKK 304,314,468, and the net result was DKK 25,012,968.
As of October 10, 2014, EY Godkendt Revisionspartnerselskab has been appointed auditor of Sanofi A/S.
As of October 10, 2014, JUT NR. 2180 A/S has stepped down as auditor of Sanofi A/S.
Sanofi A/S has published its annual report for 2013. Revenue came to DKK 255,285,136, and the net result was DKK -16,167,698.
As of October 9, 2013, is registered as an owner of Sanofi A/S with an ownership share of 100%.
Sanofi A/S has published its annual report for 2012.
As of November 9, 2012, Kirstin Jagd has joined the board of directors of Sanofi A/S.
As of November 9, 2012, Flemming Lauritzen has left the board of directors of Sanofi A/S.
As of May 31, 2012, Minna Satu Marketta Kallio has joined the board of directors of Sanofi A/S.
As of May 30, 2012, Jean Laurent Dousset has left the board of directors of Sanofi A/S.
As of November 15, 2011, Stéphane Marie Jean Amédée Malphettes has left the board of directors of Sanofi A/S.
As of May 31, 2011, JUT NR. 2180 A/S has been appointed auditor of Sanofi A/S.
As of May 31, 2011, A/S PSE NR. 4820 has stepped down as auditor of Sanofi A/S.
As of May 31, 2011, Stéphane Marie Jean Amédée Malphettes has joined the board of directors of Sanofi A/S.
As of October 1, 2009, Jean Laurent Dousset has joined the board of directors of Sanofi A/S.
As of October 1, 2009, Karen Lykke Sørensen has left the board of directors of Sanofi A/S.
As of September 1, 2008, Karen Lykke Sørensen has joined the board of directors of Sanofi A/S.
As of September 1, 2008, Lasse Richter Petersen has joined the board of directors of Sanofi A/S.
As of September 1, 2008, Colette Mutschler has left the board of directors of Sanofi A/S.
As of September 1, 2008, Lasse Richter Petersen is registered as adm. dir. of Sanofi A/S.
As of September 1, 2008, Karen Lykke Sørensen has stepped down as adm. dir. of Sanofi A/S.
As of January 1, 2007, Colette Mutschler has joined the board of directors of Sanofi A/S.
As of January 1, 2007, Jean-Marie Argeles has left the board of directors of Sanofi A/S.
As of April 18, 2006, Jean-Marie Argeles has joined the board of directors of Sanofi A/S.
As of April 18, 2006, Peter Antoon Hugo Guenter has left the board of directors of Sanofi A/S.
As of January 2, 2006, Joannes Victor Maria Hendrickx has left the board of directors of Sanofi A/S.
As of January 2, 2006, Karen Lykke Sørensen is registered as adm. dir. of Sanofi A/S.
As of January 2, 2006, Joannes Victor Maria Hendrickx has stepped down as adm. dir. of Sanofi A/S.
As of June 30, 2005, A/S PSE NR. 4820 has been appointed auditor of Sanofi A/S.
As of June 30, 2005, Pricewaterhouse Coopers has stepped down as auditor of Sanofi A/S.
As of November 26, 2004, Joannes Victor Maria Hendrickx has joined the board of directors of Sanofi A/S.
As of November 26, 2004, Peter Antoon Hugo Guenter has joined the board of directors of Sanofi A/S.
As of November 26, 2004, Per Aage Gregor Christensen has left the board of directors of Sanofi A/S.
As of November 26, 2004, Seppo Antero Silander has left the board of directors of Sanofi A/S.
As of November 26, 2004, Joannes Victor Maria Hendrickx is registered as adm. dir. of Sanofi A/S.
As of November 26, 2004, Per Aage Gregor Christensen has stepped down as director of Sanofi A/S.
As of May 7, 2001, Seppo Antero Silander has joined the board of directors of Sanofi A/S.
As of May 7, 2001, Roger Hemingway has left the board of directors of Sanofi A/S.
As of May 30, 2000, Flemming Lauritzen has joined the board of directors of Sanofi A/S.
As of May 30, 2000, Roger Hemingway has joined the board of directors of Sanofi A/S.
As of May 30, 2000, Ursula Sara Barbro Tengelin has left the board of directors of Sanofi A/S.
As of May 30, 2000, Philip Oswald Burchard has left the board of directors of Sanofi A/S.
As of December 16, 1999, Per Aage Gregor Christensen is registered as director of Sanofi A/S.
As of December 16, 1999, Ursula Sara Barbro Tengelin has stepped down as director of Sanofi A/S.
As of April 23, 1996, Erik Tronborg Andersen has stepped down as auditor of Sanofi A/S.
As of April 23, 1996, Per Aage Gregor Christensen has joined the board of directors of Sanofi A/S.
As of April 23, 1996, Ursula Sara Barbro Tengelin has joined the board of directors of Sanofi A/S.
As of April 23, 1996, Philip Oswald Burchard has joined the board of directors of Sanofi A/S.
As of April 23, 1996, Hans Christian Galst has left the board of directors of Sanofi A/S.
As of April 23, 1996, Ulf Svejgaard Poulsen has left the board of directors of Sanofi A/S.
As of April 23, 1996, Per Emil Hasselbalch Stakemann has left the board of directors of Sanofi A/S.
As of April 23, 1996, Ursula Sara Barbro Tengelin is registered as director of Sanofi A/S.
As of April 23, 1996, Per Emil Hasselbalch Stakemann has stepped down as director of Sanofi A/S.
As of January 15, 1996, Erik Tronborg Andersen has been appointed auditor of Sanofi A/S.
As of January 15, 1996, Pricewaterhouse Coopers has been appointed auditor of Sanofi A/S.
As of January 15, 1996, Hans Christian Galst has joined the board of directors of Sanofi A/S.
As of January 15, 1996, Ulf Svejgaard Poulsen has joined the board of directors of Sanofi A/S.
As of January 15, 1996, Per Emil Hasselbalch Stakemann has joined the board of directors of Sanofi A/S.
As of January 15, 1996, Per Emil Hasselbalch Stakemann is registered as director of Sanofi A/S.
Sanofi A/S was founded on January 15, 1996.
Companies in the same industry and area
CVR 37726508
CVR 16938106
CVR 27293972
CVR 45328244
CVR 41747978
